Skip to main content
Back
Watch Compare

Propanc Biopharma, Inc.

Data quality: 83%
PPCB
Nasdaq Manufacturing Chemicals
$0.10
▼ $0.03 (-20.63%)
Mkt Cap: 2.10 M
Price
$0.10
Mkt Cap
2.10 M
Day Range
$0.10 — $0.12
52-Week Range
$0.10 — $11.00
Volume
1,925,120
Open $0.12
50D / 200D Avg
$0.18
44.01% below
50D / 200D Avg
$2.01
95.03% below

Quick Summary

Key Takeaways

Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -3.11 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-532.52%
Below sector avg (-53.41%)
ROIC-397.29%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
0.01
Below sector avg (0.31)
Current Ratio2.13
Interest Coverage-90.02

Valuation

PE (TTM)
-0.03
Above sector avg (-1.48)
P/B Ratio0.20
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E 0.0 -1.5
P/B 0.2 1.6
ROE % -532.5 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E 0.0 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -66.07 M
ROE -532.52% ROA -399.36%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3.11 M
ROIC -397.29% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.01 Current Ratio 2.13
Interest Coverage -90.02 Asset Turnover N/A
Working Capital 4.08 M Tangible Book Value 10.45 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.03 Forward P/E N/A
P/B Ratio 0.20 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -148.03%
Market Cap 2.10 M Enterprise Value 2.15 M
Per Share
EPS (Diluted TTM) 52.10 Revenue / Share N/A
FCF / Share -0.15 OCF / Share -0.15
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 4.70%
SBC-Adj. FCF -10.11 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -58.92 M -1.82 M -2.66 M -2.66 M -2.42 M
EPS (Diluted) -14.85 -0.02 -1.80 — —
Gross Profit — — — — —
Operating Income -57.28 M -1.54 M -1.78 M -1.99 M -1.81 M
EBITDA — — — — —
R&D Expenses 223,721.0 248,102.0 247,919.0 256,052.0 230,956.0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 563,757.0 665,841.0 532,821.0 568,798.0 449,457.0
Income Tax -129,132.0 -129,132.0 -129,841.0 -54,977.0 -113,415.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19.63 M 72,365.0 60,328.0 81,651.0 13,101.0
Total Liabilities 5.73 M 3.85 M 3.18 M 3.11 M 3.08 M
Shareholders' Equity 13.91 M -3.78 M -3.12 M -3.02 M -3.07 M
Total Debt 537,921.0 399,325.0 390,539.0 984,260.0 624,583.0
Cash & Equivalents — — — 4,067.0 2,255.0
Current Assets 8.35 M 25,441.0 19,039.0 15,030.0 6,596.0
Current Liabilities 5.58 M 3.79 M 3.16 M 3.06 M 3.08 M